Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream for the Treatment of Vitiligo

Opzelura is the first and only FDA-approved product for repigmentation in nonsegmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improvements in facial and total body repigmentation Fifty-two week...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news